$160.00
Manufacturer: Ukraine
Adjuvant therapy in women with invasive early-stage breast cancer with a positive test for estrogen receptors in the postmenopausal period after 2-3 yEars and Nose of initial adjuvant therapy with tamoxifen. Treatment of advanced breast cancer in women with natural or induced postmenopausal status, in which the progression of the disease was detected after antiestrogen therapy. Ni has been shown to be effective in patients with a negative test for estrogen receptors.Adjuvant therapy in women with invasive early-stage breast cancer with a positive test for estrogen receptors in the postmenopausal period after 2-3 yEars and Nose of initial adjuvant therapy with tamoxifen. Treatment of advanced breast cancer in women with natural or induced postmenopausal status, in which the progression of the disease was detected after antiestrogen therapy. Ni has been shown to be effective in patients with a negative test for estrogen receptors.
Description
Ecsemevista Composition
active substance: exemestane;
1 coated tablet contains exemestane 25 mg;
Ecsemevista excipients: mannitol (E 421), hypromellose, crospovidone, polysorbate 80, microcrystalline cellulose, sodium starch, magnesium stearate, colloidal silicon dioxide, sodium carboxymethyl cellulose (E 466), maltodextrin, glucose stearic acid, titanium dioxide (E 171) (E 570), iron oxide yellow (E172), purified water.
Ecsemevista Dosage form
Film-coated tablets.
Basic physical and chemical properties: yellow, biconvex, round film-coated tablets with “E9MT” engraving on one side and “25” on the other.
Pharmacotherapeutic group
Hormone antagonists and similar agents. Aromatase inhibitors. ATX code L02B G06.
Pharmacodynamics
Mechanism of action
Exemestane is an irreversible steroidal aromatase inhibitor similar in structure to the naturally occurring substance androstenedione. In postmenopausal women, estrogens are produced primarily by converting androgens to estrogens under the action of the aromatase enzyme in peripheral tissues. Blocking estrogen production by inhibiting aromatase is an effective and selective treatment for hormone-dependent breast cancer in postmenopausal women. In postmenopausal women, exemestane significantly reduced the concentration of estrogens in the serum, starting from a dose of 5 mg, the maximum decrease (> 90%) is achieved with a dose of 10-25 mg. In postmenopausal patients diagnosed with breast cancer, who received 25 mg daily, the total level of aromatase decreased by 98%.
Exemestane has no progestogenic and estrogenic activity. Small androgenic activity, probably associated with the 17-hydroderivative, was observed mainly with the use of the drug in high doses. During studies of long-term daily use of exemestane did not affect the biosynthesis of hormones such as cortisol or aldosterone in the adrenal glands, the level of which was measured before or after the ACTH test (ACTH), this demonstrated selectivity in relation to other enzymes involved in steroid metabolism.
Indications
Adjuvant therapy in postmenopausal women with early-stage invasive breast cancer with a positive test for estrogen receptors after 2-3 years of initial adjuvant tamoxifen therapy.
Treatment of advanced breast cancer in women with natural or induced postmenopausal status in whom disease progression after anti-estrogen therapy has been identified. Neither has been demonstrated to be effective in patients with a negative test for estrogen receptors.
Contraindications
EczemeVista is contraindicated in patients with hypersensitivity to exemestane or to any other component of the drug. The drug is also contraindicated in the premenopausal period, women during pregnancy and lactation.
Recent Reviews